share_log

Evaluating TG Therapeutics: Insights From 4 Financial Analysts

Benzinga ·  Sep 19 05:01

During the last three months, 4 analysts shared their evaluations of TG Therapeutics (NASDAQ:TGTX), revealing diverse outlooks from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings30100
Last 30D10000
1M Ago00000
2M Ago20100
3M Ago00000

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $38.0, a high estimate of $49.00, and a low estimate of $20.00. Observing a 4.83% increase, the current average has risen from the previous average price target of $36.25.

1726693292_0.png

Breaking Down Analyst Ratings: A Detailed Examination

A clear picture of TG Therapeutics's perception among financial...

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment